Galderma Group AG
Extension Study for 43USSA1705
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 38
- Registration Number
- NCT04225273
- Locations
- 🇺🇸
Galderma Study Site, Spring, Texas, United States
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 500
- Registration Number
- NCT04204616
- Locations
- 🇺🇸
Galderma Investigational Galderma Investigational Site, Springville, Utah, United States
🇺🇸Galderma I Galderma Investigational Site, Lake Bluff, Illinois, United States
🇩🇪Galderme Investigational Site, Berlin, Germany
Restylane-L for Correction of Infraorbital Hollows
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 333
- Registration Number
- NCT04154930
- Locations
- 🇺🇸
Galderma Research Site, Spring, Texas, United States
Sculptra for Correction of Midface Volume Deficit and/or Midface Contour Deficiency
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 205
- Registration Number
- NCT04132518
- Locations
- 🇨🇳
Galderma research site 2, Guangzhou, China
🇨🇳Galderma research site 6, Hangzhou, China
🇨🇳Galderma research site 1, Shanghai, China
Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 149
- Registration Number
- NCT04124692
- Locations
- 🇺🇸
Galderma Research Site, Spring, Texas, United States
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
- Conditions
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 557
- Registration Number
- NCT04085367
- Locations
- 🇺🇸
Galderma Investigational Site (Site 8860), Atlanta, Georgia, United States
🇺🇸Galderma Investigational Site (Site 8734), Pembroke Pines, Florida, United States
🇺🇸Galderma Investigational Site (Site 8595), Dublin, Ohio, United States
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands
- Conditions
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 80
- Registration Number
- NCT04080882
- Locations
- 🇺🇸
Galderma Research Site, New York, New York, United States
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 1700
- Registration Number
- NCT03989206
- Locations
- 🇺🇸
Galderma Investigational Site 8206, Norman, Oklahoma, United States
🇺🇸Galderma Investigational Site 8737, Miami, Florida, United States
🇺🇸Galderma Investigational Site 8706, Miami, Florida, United States
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 787
- Registration Number
- NCT03989349
- Locations
- 🇺🇸
Galderma Investigational Site 8721, Pittsburgh, Pennsylvania, United States
🇺🇸Galderma Investigational Site 8807, Houston, Texas, United States
🇺🇸Galderma Investigational Site 8719, Miami, Florida, United States
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 941
- Registration Number
- NCT03985943
- Locations
- 🇨🇦
Galderma Investigational Site 8336, Toronto, Ontario, Canada
🇺🇸Galderma Investigational Site 8882, Bangor, Maine, United States
🇵🇱Galderma Investigational Site 6243, Gdańsk, Poland